COVID-19 Vaccination in 2025 and 2026: JCVI’s Strategic Recommendations

22 November, 2024

The Joint Committee on Vaccination and Immunisation (JCVI) has outlined its recommendations for COVID-19 vaccinations in 2025 and 2026. This targeted approach prioritises protecting the most vulnerable groups, including older adults and immunosuppressed individuals, ensuring the NHS continues to adapt to the evolving pandemic.

Introduction

The Joint Committee on Vaccination and Immunisation (JCVI) has published its latest guidance for the COVID-19 vaccination programme for spring 2025, autumn 2025, and spring 2026. This advice prioritises protecting the most vulnerable groups and ensuring the vaccination strategy remains effective and cost-efficient. Here’s what you need to know about the updated recommendations.

Spring 2025 Vaccination Programme

The JCVI has outlined a targeted approach for spring 2025, recommending COVID-19 vaccinations for the following high-risk groups:

Adults aged 75 years and over
Residents in care homes for older adults
Individuals aged 6 months and over who are immunosuppressed

These groups have been prioritised due to their increased risk of severe illness and hospitalisation from COVID-19. The spring programme aims to bolster their immunity ahead of any potential surge in infections.

Looking Ahead: Autumn 2025 and Spring 2026

For autumn 2025 and spring 2026, the JCVI continues to recommend vaccinations for the same high-risk groups. This consistent approach underscores the importance of ongoing protection for those most vulnerable to severe outcomes.

The JCVI’s strategy reflects an evidence-based approach, aligning with the evolving nature of the pandemic and the continued threat of new variants.

Ensuring Cost-Effectiveness and Value

The JCVI has emphasised the importance of ensuring that the vaccination programme remains cost-effective. By focusing on individuals at the highest risk of hospitalisation and mortality, the programme ensures that resources are directed where they are most needed.

The selection of vaccines will also be guided by their efficacy and suitability for these priority groups, ensuring maximum protection while optimising public health outcomes.

Adapting to a Changing Pandemic Landscape

The JCVI’s guidance highlights its commitment to adapting vaccination strategies based on the latest evidence and epidemiological trends. With these recommendations, the UK continues to prioritise the health and safety of its most vulnerable populations while maintaining a balanced approach to resource allocation.

Conclusion

As we move into 2025 and 2026, the JCVI’s targeted vaccination strategy aims to provide robust protection for those most at risk. By focusing on older adults, care home residents, and immunosuppressed individuals, the UK’s COVID-19 vaccination programme continues to evolve to meet the demands of a changing pandemic landscape.

This guidance serves as a reminder of the ongoing need for vigilance and adaptability in the face of COVID-19.

Check out our other articles: Resources